Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: A systematic review

Thorax

Volumn 63, Issue 5, 2008, Pages 453-462

  Joos, S ^a   Miksch, A ^a   Szecsenyi, J ^a   Wieseler, B ^b   Grouven, U ^b   Kaiser, T ^b   Schneider, A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID DERIVATIVE; FLUTICASONE; MONTELUKAST; PLACEBO; SALMETEROL;

ADD ON THERAPY; ARTICLE; ASTHMA; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DATA BASE; DATA SYNTHESIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; EMBASE; HUMAN; MEDLINE; MONOTHERAPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACETATES; ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 43949129790     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.081596     Document Type: Article

References (50)

1. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645-55.
2. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.
3. Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999;14:12-18.
4. Currie GP, Lipworth BJ. Bronchoprotective effects of leukotriene receptor antagonists in asthma: a meta-analysis. Chest 2002;122:146-50.
5. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003;326:621.
6. National Institute of Health. Global Initiative for Asthma-Global Strategy for Asthma Management and Prevention Update 2005. http://www.ginasthma. com/Guidelineitem.asp??l1=2&I2=1&intld=60 (accessed 4 November 2007).
7. ÄZQ. Nationale Versorgungsleitlinie Asthma (National Guideline for Asthma Care). http://www.versorgungsleitlinien.de/themen/asthma/ langfassung/index_html (accessed 4 November 2007).
8. British Thoracic Society. The BTS/SIGN 2004 Update of British Guideline on the Management of Asthma. http://www.enterpriseportal2.co.uk/ filestore/bts/asthmaupdatenov05.pdf (accessed 4 November 2007).
9. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ 2002;324:1545.
10. Ram FS, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev. Chichester: Wiley InterScience, 2005:CD003137.
11. European Medicines Agency EMEA. 2006. http://www.emea.eu.int/pdfs/ human/ewp/292201en.pdf#search=%22emea%20asthma%20study%22 (accessed 4 November 2007).
12. Sin DD, Man J, Sharpe H, et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004;292:367-76.
13. Kankaanranta H, Lahdensuo A, Moilanen E, et al. Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res 2004;5:17.
14. IQWIG. Leukotrien-Rezeptor-Antagonisten bei Patienten mit Asthma bronchiale (Leukotriene receptor antagonists in patients with asthma bronchiale), 2006. http://www.iqwig.de/download/A05- 14_Abschlussbericht_Leukotrien-Receptor-Antagonisten_bei_Asthma_bronchiale.pdf (accessed 19 November 2007).
15. IQWIG. Methods. Version 09_11_2005 ed. Institute for Quality and Efficiency in Health Care, 2005.http://www.iqwig.de/download/Methoden_1QWiG_V-2- 0.pdf (accessed 19 November 2007).
16. US Food and Drug Administration FDA, 2006. http://www.fda.gov/CDER/DRUG/ InfoSheets/HCP/salmeterolHCP.pdf#search=%22fda%20long-acting%20smart%22 (accessed 4 November 2007).
17. Egger M, Smith GD, Altman DG. Systematic reviews in health care - Meta-analysis in context. London: BMJ Publishing, 2001.
18. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999;160:1862-8.
19. Riccioni G, Ballone E, D'Orazio N, et al. Effectiveness of montelukast versus budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma. Int J Immunopathol Pharmacol 2002;15:149-55.
20. Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58:204-10.
21. Kanniess F, Richter K, Janicki S, et al. Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma. Eur Respir J 2002;20:1080-7.
22. Löfdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319:87-90.
23. Riccioni G, Vecchia RD, Castronuovo M, et al. Tapering dose of inhaled budesonide in subjects with mild-to-moderate persistent asthma treated with montelukast: a 16-week single-blind randomized study. Ann Clin Lab Sci 2005;35:285-9.
24. Tohda Y, Fujimura M, Taniguchi H, et al. Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin Exp Allergy 2002;32:1180-6.
25. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003;327:891.
26. GlaxoSmithKline. A phase IV, multicentre, randomised, double-blind, single dummy, parallel group study to compare the anti-inflammatory action of Seretide™ 50 MDI b.d. with Flixotide™ 50 ug MDI b.d. plus montelukast 10 mg o.d. for 12 weeks, in adults with mild to moderate asthma who are currently taking inhaled corticosteroids but have a requirements for further therapy - Study SAM40030 (SOLTA - Seretide Or addition of a Leukotriene antagonist in the Treatment of Asthma). Glaxo Smith Kline Report No SAM40030R 2004.
27. Grosclaude M, Cerruti JL, Delannay B, et al. A fixed combination of fluticasone and salmeterol permits better control of asthma than a beclomethasone dipropionate and montelukast combination. Allergy Immunol (Paris) 2003;35:356-62.
28. Ilowite J, Webb R, Friedman B, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004;92:641-8.
29. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106:1088-95.
30. Ringdal N, Eliraz A, Pruzinec R, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003;97:234-41.
31. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211-16.
32. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001;120:423-30.
33. Tattersfield AE, Knox AJ, Britton JR, et al. Asthma. Lancet 2002;360:1313-22.
34. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352:1519-28.
35. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6.
36. Adams NP, Bestall JB, Malouf R, et al. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev. Chichester: Wiley InterScience, 2005:CD002738.
37. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
38. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting {beta}-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-12.
39. Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med 1998;158:S146-53.
40. Williamson PR, Gamble C, Altman DG, et al. Outcome selection bias in meta-analysis. Stat Methods Med Res 2005;14:515-24.
41. Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 2005;365:974-6.
42. MSD SHARP&DOHME GMBH. A randomised, double-blind, multicenter study to evaluate the effect of adding either montelukast sodium or salmeterol xinafoate to inhaled fluticasone in adult asthmatics (IMPACT Study - Investigation of Montelukast as a Partner Agent for Complementary Therapy) - Study 908-0C. 2002; MSD CDSP Singulair 908-0C Statistical Report.
43. MSD SHARP&DOHME GMBH. A randomized, double-blind multicenter study to evaluate the effects of adding either montalukast sodium or salmeterol xinafoate to inhaled fluticasone in adult asthmatics - Study MK-0476 120-01 (SNG 477). 2001; MSD Results Synopsis.
44. Glaxo Wellcome. A multicenter, randomized, double-blind parallel group, 12 week active control comparison of salmeterol/fluticasone propionate combination product (50/100 mcg BID) via the DISKUS inhaler with fluticasone propionate (100 mcg BID) via the DISKUS plus oral montelukast (10 mg QD) in adults and adolescents with persistent asthma experiencing symptoms on inhaled corticosteroid therapy - Study SAS40018. 2000; Glaxo Wellcome Report No RM2000/00232/00.
45. GlaxoSmithKline. A multi-center, randomized, double-blind, double dummy, parallel-group, 12 week active control comparison of salmeterol/ fluticasone propionate combination product (50/100 mcg BID) via the DISKUS inhaler with fluticasone propionate (100 mcg BID) via the DISKUS plus oral montelukast (10 mg QD) in adults and adolescents with persistent asthma experiencing symptoms on inhaled corticosteroid therapy - study SAS40018. http://ctr.gsk.co.uk/Summary/fluticasone_salmeterol/studylist.asp (accessed 4 November 2007).
46. GlaxoSmithKline. A multicentre, randomised, double-blind, double-dummy, parallel group, 12-week, active control comparison of the salmeterol/fluticasone propionate combination product (50/100 mcg strength) bd via the DISKUS/ACCUHALER inhaler with fluticasone propionate (100 mcg strength) bd via the DISKUS/ACCUHALER inhaler plus oral montelukast 10 mg od in adolescents and adults with reversible airways obstruction - study SAS40015. 2003; GlaxoSmithKline Report No BP2001/00015/00.
47. GlaxoSmithKline. A multicentre, randomised, double-blind, double-dummy, parallel-group, 12-week, active control comparison of the salmeterol/fluticasone propionate combination product (50/100 mcg strength) bd via the DISKUS/ACCUHALER inhaler with fluticasone propionate (100 mcg strength) bd via the DISKUS/ACCUHALER inhaler plus oral montelukast 10 mg od in adolescents and adults with reversible airways obstruction - Study SAS40015. http://ctr.gsk.co.uk/Summary/fluticasone_salmeterol/studylist.asp (accessed 4 November 2007).
48. GlaxoSmithKline. A phase IV, multicentre, randomised, double blind, single dummy, parallel group study to compare the anti-inflammatory action of Seretide 50/100 bd via MDI with Flixotide 100 ug bd via MDI plus Montelukast 10 mg od for 12 weeks in adults with mild to moderate asthma who are currently taking inhaled corticosteroids but have a requirement for further therapy - study SAM40030. http://ctr.gsk.co.uk/Summary/fluticasone_salmeterol/ studylist.asp (accessed 4 November 2007).
49. Holt S, Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323:253-6.
50. Masoli M, Holt S, Weatherall M, et al. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J 2004;23:552-8.